Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Friday

Iterum Therapeutics (NASDAQ:ITRM) will likely be issuing its results before the market opens on Friday, February 6th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $0.5050 million for the quarter.

Iterum Therapeutics (NASDAQ:ITRM) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.07). The firm had revenue of $0.39 million during the quarter.

Iterum Therapeutics Stock Performance

NASDAQ ITRM opened at $0.31 on Friday. The business’s fifty day moving average is $0.37 and its 200 day moving average is $0.59. Iterum Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.75. The company has a market capitalization of $16.69 million, a PE ratio of -0.42 and a beta of 2.87.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Wall Street Zen downgraded Iterum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Iterum Therapeutics in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.00.

Institutional Trading of Iterum Therapeutics

A hedge fund recently bought a new stake in Iterum Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Iterum Therapeutics PLC (NASDAQ:ITRM) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 47,131 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.10% of Iterum Therapeutics as of its most recent SEC filing. 9.21% of the stock is currently owned by institutional investors and hedge funds.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).